Strategic Partnerships OncoNano has a recent collaboration with Gilead Sciences to evaluate ON-BOARD encapsulation with a Gilead drug candidate, indicating openness to co-development and large pharma partnerships that sales teams can leverage to propose joint opportunities with complementary portfolios.

Clinical Focus As a clinical-stage biotechnology company with preclinical and upcoming presentations at AACR and ASCO, there is a pipeline-driven sales angle to introduce partnerships for later-stage development, manufacturing support, or co-funding of clinical programs.

Platform Differentiation ON-BOARD a pH-activated, polymeric micelle platform targeting acidic tumor microenvironments offers a unique value proposition for payloads ranging from small molecules to biologics, presenting cross-therapy licensing and collaboration avenues with companies seeking targeted delivery improvements.

Leadership Momentum Recent executive appointment of Kartik Krishnan as CEO and Head of R&D, along with the COO hire in 2025, signals leadership depth and strategic execution, which can be used to approach investors or strategic partners emphasizing strong governance and path to commercialization.

Market Readiness Revenue range and substantial funding indicate a solid foundation for scale, suggesting opportunities to engage contract development and manufacturing organizations, CROs, or biotech service providers for scalable production, regulatory support, and early-access programs to accelerate time-to-market.